News & Updates

Show Multimedia Only

Fostamatinib safe, effective in moderate-to-severe hidradenitis suppurativa

07 Oct 2023

Treatment with fostamatinib, a spleen tyrosine kinase inhibitor that targets B cells and plasma cells, is well tolerated by patients with hidradenitis suppurativa (HS), resulting in improved clinical outcomes with no serious adverse events, a study has shown.

Fostamatinib safe, effective in moderate-to-severe hidradenitis suppurativa

07 Oct 2023

Too much animal-based protein poses increased AD risk

28 Sep 2023 by

Frequent intake of high-protein foods in diets, especially those derived from animals, appears to be associated with an increased risk of atopic dermatitis (AD) and allergic sensitization to common house dust mites, according to a study.

Too much animal-based protein poses increased AD risk

28 Sep 2023

Chronic wounds cost Singapore 0.07% of GDP

26 Sep 2023 by

Chronic wounds impose a substantial economic burden on Singapore, costing the country approximately 0.07 percent of its gross domestic product (GDP) annually, as reported in a study.

Chronic wounds cost Singapore 0.07% of GDP

26 Sep 2023

Dupilumab beneficial in treatment of bullous pemphigoid

24 Sep 2023

Treatment with dupilumab appears to be safe and effective in the treatment of patients with bullous pemphigoid (BP), yielding significant improvements in symptoms with a favourable safety profile, according to a study.

Dupilumab beneficial in treatment of bullous pemphigoid

24 Sep 2023

Does UV-B phototherapy increase the risk of skin cancer in AD patients?

18 Sep 2023

Ultraviolet (UV)-B phototherapy does not appear to increase the risk of skin cancer in patients with atopic dermatitis (AD), reveals a study.

Does UV-B phototherapy increase the risk of skin cancer in AD patients?

18 Sep 2023

Bimekizumab safe, effective in moderate-to-severe plaque psoriasis

18 Sep 2023 by

The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.

Bimekizumab safe, effective in moderate-to-severe plaque psoriasis

18 Sep 2023

Atopic dermatitis linked to subsequent IBD

05 Sep 2023

Children and adults with atopic dermatitis (AD) are at risk of inflammatory bowel disease (IBD), with the risk varying by age, AD severity, and IBD subtype, according to a study.

Atopic dermatitis linked to subsequent IBD

05 Sep 2023

Jakinibs for AD in Asians: Is one better than the other?

31 Aug 2023 by

Treatment with oral Janus kinase (JAK) inhibitors or jakinibs appeared well tolerated in patients with atopic dermatitis (AD) as shown in an Asian retrospective cohort study.

Jakinibs for AD in Asians: Is one better than the other?

31 Aug 2023

Prof Katalin Karikó: mRNA technology a versatile tool to transform the future of medicine

30 Aug 2023 by

At an honorary degree conferment ceremony held at the Chinese University of Hong Kong and an interview with MIMS Doctor, Professor Katalin Karikó, a pioneer of mRNA technology, suggested that recent advances in mRNA research can provide a versatile tool for combating various diseases.

Prof Katalin Karikó: mRNA technology a versatile tool to transform the future of medicine

30 Aug 2023

Topical COX inhibitor mitigates capecitabine-associated HFS in GI cancer patients

23 Aug 2023 by

Topical diclofenac gel significantly reduced the incidence of hand-foot syndrome (HFS) in patients with gastrointestinal (GI) cancer receiving capecitabine, according to findings from the exploratory subgroup analysis of the D-ToRCH* trial.

Topical COX inhibitor mitigates capecitabine-associated HFS in GI cancer patients

23 Aug 2023

News & Updates

Filter by Specialty:

Specialty:

Fostamatinib safe, effective in moderate-to-severe hidradenitis suppurativa

Fostamatinib safe, effective in moderate-to-severe hidradenitis suppurativa

Too much animal-based protein poses increased AD risk

Too much animal-based protein poses increased AD risk

Chronic wounds cost Singapore 0.07% of GDP

Chronic wounds cost Singapore 0.07% of GDP

Dupilumab beneficial in treatment of bullous pemphigoid

Dupilumab beneficial in treatment of bullous pemphigoid

Does UV-B phototherapy increase the risk of skin cancer in AD patients?

Does UV-B phototherapy increase the risk of skin cancer in AD patients?

Bimekizumab safe, effective in moderate-to-severe plaque psoriasis

Bimekizumab safe, effective in moderate-to-severe plaque psoriasis

Atopic dermatitis linked to subsequent IBD

Atopic dermatitis linked to subsequent IBD

Jakinibs for AD in Asians: Is one better than the other?

Jakinibs for AD in Asians: Is one better than the other?

Prof Katalin Karikó: mRNA technology a versatile tool to transform the future of medicine

Prof Katalin Karikó: mRNA technology a versatile tool to transform the future of medicine

Topical COX inhibitor mitigates capecitabine-associated HFS in GI cancer patients

Topical COX inhibitor mitigates capecitabine-associated HFS in GI cancer patients